NCT02623127View on ClinicalTrials.gov

A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma

PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 31, 2015

Primary Completion Date

December 31, 2017

Study Completion Date

October 31, 2018

Conditions
Thymic Carcinoma
Interventions
DRUG

Sunitinib

Trial Locations (1)

463-707

Seoul National University Bundang Hospital, Seongnam

All Listed Sponsors
collaborator

SMG-SNU Boramae Medical Center

OTHER

lead

Seoul National University Hospital

OTHER

NCT02623127 - A Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma | Biotech Hunter | Biotech Hunter